Objective. The differences between seronegative and seropositive rheumatoid arthritis (RA) have not been widely reported. We performed electronic health record (EHR)-based phenome-wide association studies (PheWAS) to identify disease associations in seropositive and seronegative RA.
Methods. A validated algorithm identified RA subjects from the de-identified version of the Vanderbilt University Medical Center EHR. Serotypes were determined by rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACPA) values. We tested EHR-derived phenotypes using PheWAS comparing seropositive RA and seronegative RA, yielding disease associations. PheWAS was also performed in RF-positive versus RF-negative subjects and ACPA-positive versus ACPA-negative subjects. Following PheWAS, select phenotypes were then manually reviewed, and fibromyalgia was specifically evaluated using a validated algorithm.
Results. A total of 2,199 RA individuals with either RF or ACPA testing were identified. Of these, 1,382 patients (63%) were classified as seropositive. Seronegative RA was associated with myalgia and myositis (odds ratio [OR] 2.1, P 5 3.7 3 10
210
) and back pain. A manual review of the health record showed that among subjects coded for Myalgia and Myositis,~80% had fibromyalgia. Follow-up with a specific EHR algorithm for fibromyalgia confirmed that seronegative RA was associated with fibromyalgia (OR 1.8, P 5 4.0 3 10
26
). Seropositive RA was associated with chronic airway obstruction (OR 2.2, P 5 1.4 3 10 24 ) and tobacco use (OR 2.2, P 5 7.0 3 10
24

).
Conclusion. This PheWAS of RA patients identifies a strong association between seronegativity and fibromyalgia. It also affirms relationships between seropositivity and chronic airway obstruction and between seropositivity and tobacco use. These findings demonstrate the utility of the PheWAS approach to discover novel phenotype associations within different subgroups of a disease.
Rheumatoid arthritis (RA) is an autoimmune, inflammatory disorder of unknown etiology. Serologic tests for rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA) are included in the 2010 American College of Rheumatology criteria for RA and classify patients into subgroups that have specific associations with genetic and environmental risk factors for RA (1) . In 5 large RA cohorts, 52-64% of patients had elevated ACPA levels, and 54-72% had elevated RF levels (2, 3) . Seronegative patients are generally not as well represented, with proportions varying between 10% and 48% in previous studies (4, 5) . Seronegative RA patients are enrolled less frequently in research cohorts or clinical trials, and as a consequence, less knowledge about this subgroup has been accumulated (6-9). Treatment guidelines for RA do not differ according to serology except to categorize seropositivity as a factor for a poor prognosis (10) .
Previous studies have shown that disease characteristics differ between seropositive and seronegative patients with RA. Older studies show that RF-seropositive patients more frequently have extraarticular manifestations, such as rheumatoid nodules and vasculitis (11, 12) , and subchondral erosions (13) . More recent data indicate that ACPA-positive patients have a higher incidence of lung disease (14) and ischemic heart disease (15, 16) . In seropositive RA patients, disease is more severe (17) , and radiographic progression is more rapid (18) . However, most studies do not consider seronegative RA as being an area of emphasis, and there is very little literature describing this subgroup.
Electronic health records (EHRs) are emerging as a tool for clinical and genomic research, including research in RA (19) (20) (21) . Although EHRs do not use standardized data collection, as would be used in a clinical trial, clinical records for a much larger number of patients are available and may contain a more diverse set of observations.
De-identified clinical data in combination with genetic data can be used in innovative ways, and one such technique is known as phenome-wide association study (PheWAS) (22) . The PheWAS was originally used to replicate known genetic associations with clinical phenotypes (derived from International Classification of Diseases, Ninth Revision [ICD-9] codes), including RA (22) . A later study validated the technique across multiple centers, scanning for associations between .3,000 singlenucleotide polymorphisms (SNPs) and EHR-derived phenotypes, and also demonstrated several novel disease associations (23) . PheWAS use has expanded beyond genetic data. In a recent study, a quantitative trait, thiopurine S-methyltransferase activity level, was used to create comparator groups by PheWAS (24). Liao et al performed PheWAS with autoantibodies, finding that anti-thyroid peroxidase antibodies were associated with acquired hypothyroidism in a population of RA patients and non-RA controls (25) . In the same study, RA patients with high-titer antinuclear antibodies were shown to have a higher prevalence of Sj€ ogren's/sicca syndrome.
We hypothesized that we can identify phenotypic differences between seropositive and seronegative RA with a PheWAS using clinical EHR data. A comparison of disease subgroups using PheWAS has not yet been published. We hope to demonstrate the ability to replicate known findings in seropositive RA and discover new differences between serotypes.
PATIENTS AND METHODS
Study population. This study was conducted using data for RA subjects from the Synthetic Derivative (SD) database, a de-identified version of the Vanderbilt University Medical Center EHR. This provides a very rich set of clinical data including clinical notes, laboratory results, radiology reports, pathology, and other clinical information for ;2.5 million individuals (26) . RA subjects were identified using an algorithm that has been validated in the Vanderbilt medical record as well as other centers, with a positive predictive value of 97% (21). This algorithm uses 21 different factors, including natural language processing of clinical records, medication exposures, radiography reports, and serology results. It also excludes subjects with symptoms that could mimic RA, such as psoriasis and systemic lupus erythematosus. We applied the algorithm to the entire SD to identify 5,634 individuals meeting the criteria for the algorithm. From these, we selected those individuals who were older than age 18 years and had at least 1 recorded serologic test in the Vanderbilt EHR system (either RF or ACPA), yielding 2,199 individuals. Age was calculated as the age at which they were first billed for RA with ICD-9 code 714.0. Clinical EHR data were restricted to records before September 27, 2013.
Serologic testing. A positive RF or ACPA test result was defined as a value above the upper limit of normal in the clinical laboratory test, according to the manufacturer. An RF assay was used to quantify RF (Beckman). ACPAs were measured by an enzyme-linked immunosorbent assay kit (Axis Shield). A subject with a positive test result for either autoantibody at any time was considered seropositive. Subjects classified as seronegative must have had negative serologic test results for all RF and ACPA tests performed at Vanderbilt. Serologic data from outside medical systems were not considered in this study, because these data were not available in the de-identified medical record.
EHR encounter data. EHR time was calculated as the number of years between the first and last billing encounters in the EHR. Five records were removed from this analysis because the follow-up times were clearly erroneous (.100 years). EHR time with RA ICD-9 codes was the number of years between the first and last billing encounters in the EHR after the diagnosis of RA. EHR billing encounters counted each billing encounter (e.g., clinic visit or hospitalization) for each subject. Of note, each day of an inpatient hospitalization was counted as a separate billing encounter. EHR billing encounters with RA ICD-9 codes was a count of all encounters that included the billing code for RA, 714.0. These data were reported as the median and interquartile range (IQR), because the data skewed right.
Phenome-wide association study. PheWAS was used to compare the phenotypes of seropositive and seronegative RA. Cases and controls for diseases in PheWAS are defined by the presence and absence of specific ICD-9 codes in a subject's billing records. PheWAS codes were derived from the ICD-9 code library by creation of "case groups" of related ICD-9 codes (23). For example, tuberculosis-related infections have many different 3-digit ICD-9 prefixes, but in PheWAS terminology these are united under a single code. An individual is considered as a case for a given phenotype when he or she has been documented for that phenotype on at least 2 different dates. This heuristic method has been used in prior PheWAS to improve the positive predictive value. An individual is considered a control for a given phenotype if he or she has zero mentions of the phenotype in question and no codes for conditions related to that phenotype (e.g., a patient coded for "cardiac arrhythmia" will not serve as a control for atrial fibrillation) (27) . For a phenotype to be included in the analysis, that phenotype must be present in at least 20 individuals. The lists of related conditions for each phenotype are described via the PheWAS code translations (available at http:// phewascatalog.org).
Three PheWAS were performed: 1) seropositive versus seronegative RA, 2) RF-positive versus RF-negative, and 3) ACPA-positive versus ACPA-negative. We used the PheWAS package in R to convert ICD-9 data to PheWAS codes and perform the primary statistical analysis (28) . For each phenotype, we constructed a logistic regression model with the phenotype as the outcome predicted by the binary exposure of seropositivity adjusted for age and sex. To adjust for multiple hypothesis testing, we considered phenotype associations to be significant if they met a false discovery rate (FDR) of 5% using the BenjaminiHochberg method. The observed minimum significant P values 292 DOSS ET AL were P 5 7.0 3 10 24 for seropositive versus seronegative, P 5 7.6 3 10
24 for RF-positive versus RF-negative, and P 5 2.9 3 10 24 for ACPA-positive versus ACPA-negative. The PheWAS R package v0.9.4 was used to calculate the PheWAS and graph results (27) .
Manual chart review. Manual chart review was necessary for the strongest association observed in PheWAS, Myalgia and Myositis (ICD-9 729.1) to determine whether the code was being used for fibromyalgia or for other causes (e.g., localized muscle aches or inflammatory muscle disease). One hundred records with $2 PheWAS codes for Myalgia and Myositis were selected randomly (50 seronegative and 50 seropositive) and were assessed for: 1) clinical diagnosis of fibromyalgia, 2) timing of diagnosis (before or after diagnosis of RA), 3) if fibromyalgia was diagnosed, whether or not treatment was specified, 4) whether RA was misdiagnosed as fibromyalgia, and 5) to validate the clinical diagnosis of RA. These data were managed within the SD, and results were exported to Stata 13.
Fibromyalgia identification algorithm. There is no known algorithm to identify fibromyalgia using EHRs. We created and evaluated an algorithm to identify fibromyalgia, which uses 1) 2 instances of ICD-9 code 729.1 and 2) any of the terms "fibromyalgia," myofascial pain," "fibrositis," "fibromyositis," or "FMS" in the clinical health record of a subject. To validate this algorithm, a physician reviewed 100 randomly selected charts that met the criteria of the algorithm. Because all individuals in this set were seen by a rheumatologist, the gold standard was a fibromyalgia diagnosis by the treating rheumatologist. The algorithm is posted on the PheKB web site (http://phekb.org).
The association between seropositivity and fibromyalgia was evaluated using a multivariable logistic regression model predicting algorithm-defined fibromyalgia, using age, sex, and serotype. Fibromyalgia algorithm-identified seropositive and seronegative subjects were assessed for differences in timing between the first documented ICD-9 code for RA and a diagnosis of fibromyalgia. Differences between groups were compared with the nonparametric Wilcoxon's rank sum test, using Stata 13.
Institutional review board approval. The Vanderbilt University Medical Center institutional review board approved this study as non-human subjects research in accordance with 45 CFR (Code of Federal Regulations) part 46, given the de-identified nature of the data, which has been described previously (26) .
RESULTS
Characteristics of the study subjects. A total of 2,199 RA cases were identified by the EHR algorithm, with 63% classified as seropositive. The baseline characteristics of the seronegative and seropositive groups are shown in Table 1 . Among the seropositive cases, 73% were women compared with 80% among the seronegative cases. The mean age was comparable between the 2 groups. The racial makeup was predominantly nonHispanic white (77% and 79% in the seropositive and seronegative groups, respectively), with African Americans making up the next largest racial group (9% and 6%, respectively). Individuals in both the seropositive group and the seronegative group were followed up in the EHR for a similar length of time (8 years) and for a (35) similar length of time after an RA diagnosis (5-6 years), and a similar number of total encounters (n 5 29). The seropositive group had slightly more encounters billed for RA than the seronegative group (median 17 versus 14). Serologic data for seropositive and seronegative subjects. Of the 2,199 subjects, 617 had both RF and ACPA testing documented in the EHR. Among these 617 subjects, 35% were positive for both RF and ACPA and 35% were negative for both RF and ACPA (Table 2) . Of the 2,001 subjects with RF tests, 63% were RF positive. Of the 815 subjects with ACPA tests, 42% were ACPA positive. In total, seropositive subjects represented 63% of the study population, and seronegative subjects represented 37% of the study population.
Phenotypes associated with seropositive and seronegative RA. Table 3 and Figure 1A show the phenotypes associated with seropositive and seronegative RA as determined by PheWAS. Seronegative RA was shown to be associated with Myalgia and Myositis (odds ratio [OR] 2.1, P 5 3.7 3 10 210 ); this was the strongest association observed in the study. Other significant associations were Spondylosis and Allied Disorders, Spondylosis without Myelopathy, Intervertebral Disc Disorders, and Internal Derangement of Knee. Chronic Airway Obstruction was the PheWAS code with the strongest association with seropositive arthritis (OR 2.2, P 5 1.4 3 10
24
). The other significant risk association with seropositive RA was Tobacco Use Disorder (OR 2.2, P 5 7.0 3 10
). We performed 2 separate PheWAS, with one using RF positivity/negativity and the other using ACPA positivity/negativity. Results for individual serologies were largely similar to those observed in the combined analysis. RF-negative RA was associated with Myalgia and Myositis (OR 2.2, P 5 7.1 3 10
210
). RF-positive RA was associated with Tobacco Use Disorder (OR 2.5, P 5 4.5 3 10
25
) and Chronic Airway Obstruction (OR 2.3, P 5 1.1 3 10 24 ) ( Figure 1B) . PheWAS using ACPA showed that ACPAnegative RA had the strongest association with Myalgia and Myositis (OR 3.0, P 5 4.5 3 10
28
). ACPA-positive RA was most strongly associated with Tobacco Use Disorder (OR 4.5, P 5 2.9 3 10 24 ) ( Figure 1C) . After limiting the analysis to the 617 subjects with both RF and ACPA measured locally, there were only 117 tests with sufficient cases (n 5 20). Myalgia and Myositis had the strongest association with seronegative RA (OR 2.6, P 5 4.5 3 10
26
). Chart review of cases with a diagnosis of fibromyalgia. To assess whether subjects with the Myalgia and Myositis phenotype (ICD-9 code 729.1) had diagnoses of fibromyalgia, a manual review of the medical chart was conducted in subjects randomly selected from both the seropositive and seronegative populations (see Table 4 ). Among the 100 charts reviewed that had $2 ICD-9 codes of 729.1, 71% of seropositive subjects and 69% of seronegative subjects had received a clinical diagnosis of fibromyalgia. Among another 8% of seropositive and 12% of seronegative subjects, treatments were recommended that strongly implied a diagnosis of fibromyalgia (e.g., pregabalin, duloxetine), but fibromyalgia was not mentioned by name. Thus, the clinical health records suggested that 79% of seropositive and 81% of seronegative subjects with this ICD-9 code 
PheWAS OF RHEUMATOID ARTHRITIS SUBGROUPS
Performance of algorithm used to identify fibromyalgia. We evaluated the performance of an algorithm that used 2 instances of ICD-9 code 729.1 and the term "fibromyalgia" in a subject's clinical documentation in 100 records. On review, a clinical diagnosis of fibromyalgia was made in 96 of these 100 individuals, for a positive predictive value of 96%.
The algorithm was then applied to 2,199 subjects and identified 281 (12.8%) individuals. A logistic regression model predicting fibromyalgia algorithm status according to serotype, sex, and age showed that fibromyalgia algorithm-positive individuals were 1.8 times more likely to have seronegative RA (P 5 4.0 3 10
26
) and 5.6 times more likely to be female (P 5 7.2 3 10 211 ). No relationship with age was observed.
The timing of the first fibromyalgia ICD-9 code and the first RA ICD-9 code was compared between seropositive and seronegative groups (Figure 2 ). This was done to assess whether one group was disproportionately being given a diagnosis of fibromyalgia before the diagnosis of RA. Among seronegative subjects, the median time between a diagnosis of RA and a diagnosis of fibromyalgia was 86 days (interquartile range [IQR] 236 to 665 days). Among seropositive individuals, the median time was 173 days (IQR 0 to 960 days). This difference trended toward but did not reach statistical significance (P 5 0.08). For both serotypes, the majority of fibromyalgia diagnoses were made within 1 year of the diagnosis of RA.
DISCUSSION
To our knowledge, this is the first published study that uses a PheWAS to compare serologically defined subgroups of a disease. This study illuminates differences between seropositive and seronegative RA, an area in which the recent literature is sparse. We observed that seronegative RA cases were 2-fold more likely to be diagnosed according to PheWAS codes indicating fibromyalgia. Seropositive RA showed multiple associations with phenotypes for pulmonary disease and were more likely to have been coded for a disorder associated with tobacco use. The findings in this analysis are robust for several reasons. We have confirmed the reliability of a previous algorithm to identify RA cases. Even if a small number of non-RA subjects enter in the study, their relative contribution to the results will be overwhelmed by the number of subjects with true RA who were included. Because these subjects were obtained from a clinical EHR, their data may be more applicable to a standard rheumatology practice as compared with research cohorts. Finally, we have used a FDR method to correct for multiple testing bias.
The strongest phenotypic association observed for seronegative RA was for Myalgia and Myositis (ICD-9 code 729.1), which corresponds to ICD-9 code 729.1, which is frequently used for fibromyalgia in clinical practice. The manual record review undertaken determined that most cases coded for Myalgia and Myositis (ICD-9 code 729.1) were in fact diagnosed as fibromyalgia. When accounting for confirmed cases and suspected cases, ;80% of patients coded with 729.1 had fibromyalgia. Past studies have shown a relationship between fibromyalgia and RA, with a prevalence as high as 12-17% (29, 30) , which is similar to what we observed in our study (12.8%). Data from the Canadian Early Arthritis cohort showed that the incidence of fibromyalgia was associated with seronegative RA (defined as ACPA negativity) with a hazard ratio of 2.1 (31) , which is consistent with our results (OR 3.0) ( Figure 1C ). We demonstrate that fibromyalgia is associated with seronegativity for both RF and ACPA.
Interestingly, the chart review showed that the seronegative group contained more patients in whom fibromyalgia was diagnosed prior to a diagnosis of RA. This could indicate that clinicians were less likely to diagnose RA in patients with negative serologies. The analysis of timing of RA and fibromyalgia ICD-9 codes addressed this concern and showed only a trend toward earlier diagnosis of fibromyalgia in seronegative individuals. Alternatively, it could also imply that fibromyalgia is the underlying diagnosis in some seronegative subjects, rather than true inflammatory disease. However, the chart review showed only 1 diagnosis of RA that was changed to fibromyalgia.
Several phenotypes associated with seronegative RA were related to back pain. The ACR 2010 diagnostic criteria for fibromyalgia (32) include upper and lower back pain as part of the widespread pain index, and low back pain is frequently observed in fibromyalgia patients (33) . It has been shown that 25% of patients who sought care for low back pain were eventually diagnosed with fibromyalgia (34) . Given the frequency and severity of musculoskeletal symptoms caused by fibromyalgia, it is not surprising to see this reflected in the PheWAS results.
The link between pulmonary pathology and RA has been well established. Some theories of RA pathogenesis implicate a pulmonary insult as being the primary mechanism leading to an immune response against citrullinated peptides (35) . Cigarette smoking is associated with seropositive RA (36) and more-severe disease with increased radiographic progression (37, 38) . A recent retrospective cohort study showed that seropositive RA subjects (defined as RF positive) have a higher incidence of obstructive lung disease than seronegative RA subjects, with a hazard ratio of 2.93 (39), similar to our effect size (OR 2.3). Our PheWAS using RF replicated these results ( Figure 1B) . Interstitial lung disease is another complication of RA that is thought to be more often associated with seropositive patients (40, 41) . This relationship was also replicated in the PheWAS.
Another association with seropositive RA that trended toward significance was for Staphylococcus infection. Seropositivity is a factor for poor prognosis as noted in the 2012 update of the ACR recommendations for the treatment of RA (10) and may lead physicians to prescribe more-intensive immunosuppressive therapy, thereby increasing the risk of infection. There are conflicting data regarding whether seropositivity leads to an increased incidence of infections. A study from the Mayo Clinic showed an increased infection risk in RF-positive patients (42) , while a recent Veteran's Health Administration study showed no difference (43) .
One notable finding in our RA population is the proportions of positivity for the RF and ACPA serotypes. To better understand how consistent our serologic data are with known RA cohorts, we compared our serologic data with aggregated totals from 4 European cohorts totaling 4,956 patients and the BRASS cohort from Brigham and Women's Hospital with a total of ;1,000 patients (2,3). Most notably, ACPA positivity was lower in our subjects (42%) compared with the European cohorts (64%) and BRASS (61%). The percentage of dual serology-positive patients was lower in our study (35%) than in the European cohorts (53%). One explanation is that the European cohorts all required patients to fulfill the ACR 1987 revised criteria for the classification of RA (44) . Fulfillment of these more stringent criteria is likely to increase the probability of ACPA positivity. The use of ACPA testing at Vanderbilt has increased greatly in the last 5 years, and with greater numbers of patients being tested it is possible that the proportion of positive results may approximate the BRASS and European data over time. RF positivity was 63% in our study, similar to 64% in the European cohorts and 57% in BRASS. Double-negative serologies were observed to be 27% in the European cohorts and 35% in our study.
There are some limitations worthy of mention. Using clinical EHR data to identify RA subjects relies on the accuracy of clinical diagnosis rather than fulfillment of the ACR 1987 or 2010 criteria. Interestingly, the proportion of RF-positive individuals was similar between our study and the aforementioned European and American cohorts, which provides confidence that the clinical diagnoses were most often correct. Another limitation of the clinical EHR is that the Disease Activity Score in 28 joints (45) or other disease severity measures are not consistently collected or recorded. Therefore, it is not possible to adjust for disease severity. However, it is noted that the number of billing encounters was similar between seropositive and seronegative groups, which may indicate similarity between groups (Table 1) .
PheWAS is most likely to be informative when all billing documentation occurs within a single medical system. If a subject was receiving primary care or was hospitalized at outside facilities, those billing codes would not be captured in the analysis, and potential disease associations could be missed. It was reassuring to observe that RA patients in our study accrued almost half of their billing from encounters not including RA diagnostic codes, implying that they were frequently seen for non-RA medical conditions, and that their phenotypic coding was more likely to be comprehensive. Misclassification of serotypes is another concern, as evidenced by 6 individuals who were defined as seronegative but had outside records showing seropositivity. Seropositive individuals misclassified as seronegative would reduce differences between the groups and thus would lead to a bias toward the null and decrease our statistical power to find associations. In spite of this, we still see significant differences based on serology status.
EHRs provide a rich data source that has been underutilized for research purposes. This has been recognized, and the Patient-Centered Outcomes Research Institute has funded Clinical Data Research Networks, which will use de-identified EHR data for as many as 25 million patients (46) . Further depth can be lent to these studies when a clinical EHR is linked to a DNA biobank, as is the case at our institution and several others (47) . Rather than using a SNP like a traditional genome-wide association study, genetic associations could be analyzed between groups defined by phenotypes, which is an exciting new direction for PheWAS to enhance understanding of disease subgroups.
Approximately 1 of every 3 RA patients is seronegative; nonetheless, very little about this subgroup and its comorbidities has been defined. This PheWAS demonstrated a strong association with fibromyalgia in seronegative RA and confirmed known tobacco-related pulmonary associations in seropositive RA. This technique can be expanded beyond RA to compare subgroups of subjects with other diseases. By repurposing EHR data originally intended for clinical use, PheWAS holds great potential for discovering new disease associations.
